Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?

Bladder Cancer

Volumn 3, Issue 4, 2017, Pages 237-244

  Nguyen, Huyen T ^a   Mortazavi, Amir ^a   Pohar, Kamal S ^a   Zynger, Debra L ^a   Wei, Lai ^a   Shah, Zarine K ^a   Jiaa, Guang ^b,c   Knopp, Michael V ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; chemotherapeutic response; diffusion weighted imaging; micro cellularity; tumor heterogeneity; water diffusivity

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; ENTROPY; FEMALE; HISTOGRAM; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEOADJUVANT CHEMOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 85050892539     PISSN: 23523727     EISSN: 23523735     Source Type: Journal    
DOI: 10.3233/BLC-170110     Document Type: Article

References (32)

1. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.NEngl JMed2003;349(9): 859-66.
2. International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, Treatment of Cancer Genito-Urinary Tract Cancer G, Australian Bladder Cancer Study G, National Cancer Institute of Canada Clinical Trials G, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171-7.
3. Sonpavde G, Lerner SP. Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park) 2007;21(14): 1673-81; discussion 86-8, 91, 94.
4. Sonpavde G, Sternberg CN. Neoadjuvant chemotherapy for invasive bladder cancer. Current Urology Reports 2012;13(2):136-46.
5. Chang JS, Lara PN, Jr., Pan CX. Progress in personalizing chemotherapy for bladder cancer. Adv Urol 2012;2012: 364919.
6. Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. European Urology 2007;52(1): 134-41.
7. Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, et al. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Clin Genitourin Cancer 2016;14(1):e59-65.
8. Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer-Does pT0 Predict Better Survival than pTa/Tis/T1? J Urol 2016;195(4 Pt 1):886-93.
9. Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, et al. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS One 2015;10(7):e0131245.
10. Nguyen HT, Jia G, Shah ZK, Pohar K, Mortazavi A, Zynger DL, et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. Journal of Magnetic Resonance Imaging: JMRI 2015;41(5):1374-82.
11. Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012;83(1):e21-7.
12. Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle:Translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 2010;70(5):1753-8.
13. Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. European Urology 2016;69(3):384-8.
14. Kato Y, Zembutsu H, Takata R, Miya F, Tsunoda T, Obara W, et al. Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp Ther Med 2011;2(1):47-56.
15. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11(7):2625-36.
16. Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol 2016;2(8):1094-6.
17. Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4(10):1140-53.
18. Davnall F, Yip CS, Ljungqvist G, Selmi M, Ng F, Sanghera B, et al. Assessment of tumor heterogeneity: An emerging imaging tool for clinical practice? Insights Imaging 2012;3(6):573-89.
19. NguyenHT, Shah ZK, Mortazavi A, Pohar KS,Wei L, Jia G, et al. Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: A phase I study. Eur Radiol 2016.
20. Srinivasan A, Galban CJ, Johnson TD, Chenevert TL, Ross BD, Mukherji SK. Utility of the k-means clustering algorithm in differentiating apparent diffusion coefficient values of benign and malignant neck pathologies. AJNR Am J Neuroradiol 2010;31(4):736-40.
21. Suo S, Zhang K, Cao M, Suo X, Hua J, Geng X, et al. Characterization of breast masses as benign or malignant at 3.0T MRI with whole-lesion histogram analysis of the apparent diffusion coefficient. Journal of Magnetic Resonance Imaging: JMRI 2015.
22. Suo ST, Chen XX, Fan Y,Wu LM, Yao QY, Cao MQ, et al. Histogram analysis of apparent diffusion coefficient at 3.0 T in urinary bladder lesions: Correlation with pathologic findings. Academic Radiology 2014;21(8):1027-34.
23. Alic L, Niessen WJ, Veenland JF. Quantification of Heterogeneity as a Biomarker in Tumor Imaging: A Systematic Review. PLoS One 2014;9(10).
24. Rose CJ, Mills SJ, O'Connor JP, Buonaccorsi GA, Roberts C, Watson Y, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009;62(2):488-99.
25. Just N. Improving tumour heterogeneity MRI assessment with histograms. Br J Cancer 2014;111(12):2205-13.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47.
27. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature 2013;501(7467):346-54.
28. Bagwell CB. DNA histogram analysis for node-negative breast cancer. Cytometry A 2004;58(1):76-8.
29. Rosenkrantz AB. Histogram-based apparent diffusion coefficient analysis: An emerging tool for cervical cancer characterization? AJR American Journal of Roentgenology 2013;200(2):311-3.
30. Rosenkrantz AB, Obele C, Rusinek H, Balar AV, Huang WC, Deng FM, et al. Whole-lesion diffusion metrics for assessment of bladder cancer aggressiveness. Abdominal Imaging 2015;40(2):327-32.
31. Choi YJ, Lee JH, Kim HO, Kim DY, Yoon RG, Cho SH, et al. Histogram Analysis of Apparent Diffusion Coefficients for Occult Tonsil Cancer in Patients with Cervical Nodal Metastasis from an Unknown Primary Site at Presentation. Radiology 2016;278(1):146-55.
32. Choi MH, Oh SN, Rha SE, Choi JI, Lee SH, Jang HS, et al. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer. Journal of Magnetic Resonance Imaging: JMRI 2016;44(1):212-20.